Bronchoalveolar lavage cell populations in bleomycin lung toxicity.

द्वारा White, D A, Kris, M G, Stover, D E
प्रकाशित 1987

Chemotherapy remains an essential element of personalized care for persons with lung cancers

द्वारा Hellmann, M. D., Li, B. T., Chaft, J. E., Kris, M. G.
में प्रकाशित Ann Oncol (2016)

Antiemetics and cytotoxic drugs.

द्वारा Kris, M G, Gralla, R J, Tyson, L B, Clark, R A
प्रकाशित 1983

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

द्वारा Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., Riely, G. J.
प्रकाशित 2014

Differences in survival of patients with recurrent versus de novo metastatic KRAS and EGFR mutant lung cancers

द्वारा Yu, H. A., Sima, C. S., Hellmann, M. D., Naidoo, J., Busby, N., Rodriguez, K., Riely, G. J., Kris, M. G.
में प्रकाशित Cancer (2015)

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers(†)

द्वारा Li, B. T., Drilon, A., Johnson, M. L., Hsu, M., Sima, C. S., McGinn, C., Sugita, H., Kris, M. G., Azzoli, C. G.
में प्रकाशित Ann Oncol (2016)

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumo...

द्वारा Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., Jänne, P. A.
में प्रकाशित Ann Oncol (2015)

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers(†)

द्वारा Yu, H. A., Sima, C., Feldman, D., Liu, L. L., Vaitheesvaran, B., Cross, J., Rudin, C. M., Kris, M. G., Pao, W., Michor, F., Riely, G. J.
में प्रकाशित Ann Oncol (2017)

Clinical Characteristics and Course of 63 patients with BRAF Mutant Lung Cancers

द्वारा Litvak, A.M., Paik, P.K., Woo, K. M., Sima, C. S., Hellmann, M. D., Arcila, M.E., Ladanyi, M., Rudin, C. M., Kris, M. G., Riely, G. J.
में प्रकाशित J Thorac Oncol (2014)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

द्वारा Schoenfeld, A.J., Arbour, K.C., Rizvi, H., Iqbal, A.N., Gadgeel, S.M., Girshman, J., Kris, M.G., Riely, G.J., Yu, H.A., Hellmann, M.D.
में प्रकाशित Ann Oncol (2019)

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

द्वारा Drilon, A., Bergagnini, I., Delasos, L., Sabari, J., Woo, K. M., Plodkowski, A., Wang, L., Hellmann, M. D., Joubert, P., Sima, C. S., Smith, R., Somwar, R., Rekhtman, N., Ladanyi, M., Riely, G. J., Kris, M. G.
में प्रकाशित Ann Oncol (2016)

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

द्वारा Sabari, J K, Leonardi, G C, Shu, C A, Umeton, R, Montecalvo, J, Ni, A, Chen, R, Dienstag, J, Mrad, C, Bergagnini, I, Lai, W V, Offin, M, Arbour, K C, Plodkowski, A J, Halpenny, D F, Paik, P K, Li, B T, Riely, G J, Kris, M G, Rudin, C M, Sholl, L M, Nishino, M, Hellmann, M D, Rekhtman, N, Awad, M M, Drilon, A
में प्रकाशित Ann Oncol (2018)

COVID-19 in patients with lung cancer

द्वारा Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.
में प्रकाशित Ann Oncol (2020)